Follow-On Biologics Market Unfolding: Big Pharma Signals An Interest
Executive Summary
Large pharmaceutical and biotechnology companies will start openly developing follow-on biologics once Congress passes legislation authorizing an abbreviated approval pathway, Cowen & Co. analyst Ken Cacciatore predicted
You may also be interested in...
Pfizer Ahead Of Guidance In India, President Of Established Products Business Unit David Simmons Tells PharmAsia News
David Simmons, President at Pfizer's Established Products Business Unit says he is very positive about his company's deals struck earlier this year with Aurobindo and Claris. The two Indian companies will help Pfizer bulk up more than 100 oral and injectable formulations and turn the business unit cash positive in the next two to three years. Pfizer will sell the loss-of-exclusivity products through its Greenstone arm in the United States will likely launch those in Europe, Japan and a host of emerging markets. PharmAsia News' India bureau sat down with Simmons to find out more about Pfizer's pipeline and plans in India.
Big Pharma’s March Into Biotech Could Make Big Biologics A Big ’09 Theme
In 2009, some of the biggest new drugs might not technically be drugs at all. Major biologic products could dominate the upcoming year, largely thanks to big pharma's maturing interest in biotechnology
Big Pharma’s March Into Biotech Could Make Big Biologics A Big ’09 Theme
In 2009, some of the biggest new drugs might not technically be drugs at all. Major biologic products could dominate the upcoming year, largely thanks to big pharma's maturing interest in biotechnology